Today we interview Dr. Josee-Lyne Ethier of Queen's University in Kingston, Ontario, Canada on her new paper "Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer", out now in JAMA Oncology. We talk about the real-world survival outcomes for pertuzumab and T-DM1, comparing these outcomes to the results of pivotal clinical trials CLEOPATRA and EMILIA. Practice Patterns and Outcomes: doi.org/10.1001/jamaoncol.2021.2140 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Plenary Session

4.12 Real-World Survival Outcomes for Pertuzumab and T-DM1 with Dr. Josee-Lyne Ethier

Today's episode is a compilation of a few short monologues. We provide an oncologist's evidence-based medicine perspective on four papers: CheckMate 274, adjuvant nivolumab in urothelial cancer; PARADIGM-HF/Entresto; the POLO trial, olaparib in pancreas cancer; and the paper "An algorithmic approach to reducing unexplained pain disparities in underserved populations". CheckMate 274: doi.org/10.1056/NEJMoa2034442 PARADIGM-HF: doi.org/10.1056/nejmoa1409077 POLO: doi.org/10.1056/NEJMoa1903387 Knee pain: doi.org/10.1038/s41591-020-01192-7 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.11 CheckMate 274, PARADIGM-HF/Ernesto, POLO, & an AI Approach to Reducing Knee Pain

Today we sit down (in person!) with Dr. Jeff Bien of Stanford University to break down all the details -- from the methods to the statistical analysis to the conclusions -- of the CheckMate 649 trial, which pitted first-line nivolumab plus chemotherapy against chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma. CheckMate 649: doi.org/10.1016/S0140-6736(21)00797-2 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.10 A Deep Dive into CheckMate 649 with Dr. Jeffrey Bien

Today we have two short monologues for you on recent papers. The first, by popular request, is the problems with the VISION trial, which treated metastatic castration-resistant prostate cancer with lutetium-177–PSMA-617 (Lu-177–PSMA-617) radioligand therapy and standard of care. The second is on the paper recently published in Science titled "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients". Fecal transplant: doi.org/10.1126/science.abb5920 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.09 Problems with the VISION Trial & Stool Transplant Plus Nivo for Metastatic Melanoma

In today's quick episode, we talk about our new paper out now in JAMA Network Open titled "The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval" ODAC Votes: doi.org/10.1001/jamaoncol.2021.3046 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.08 Implications for the Fate of Accelerated Approval from the ODAC Votes of April 2021

We have a reverse episode for you today! Emma Greenstreet, a second-year medical student at UCSF, interviews our usual host, Dr. Vinay Prasad on why and how he chose hematology/oncology as a specialty, engaging with criticism, mentorship, medical student rotations, choosing a research project, and urging doctors in academia to aim higher. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.07 Questions from a Medical Student with Emma Greenstreet and Dr. Vinay Prasad

We sat down in person with Dr. Rahul Banerjee, a BMT/CAR-T fellow at UCSF, to talk about all manner of topics including CAR-T, randomized trials in oncology (and, specifically, Dr. Banerjee's two recent papers out now), social media, treating Multiple Myeloma, and how people make career decisions. What Oncologists Can Learn From COVID-19: doi.org/10.1038/s41571-020-00448-y Are Observational, Real-World Studies Suitable: doi.org/10.1001/jamanetworkopen.2020.12119 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.06 CAR-T, Oncology RCTs, Social Media, Myeloma, and Career Decisions with Dr. Rahul Banerjee

Today we are joined by Dr. Ameet Sarpatwari of Harvard Medical School to discuss how so many great minds in oncology are leaving cancer research in academia for industry. We also talk about the evidence (or lack thereof) behind the recent FDA approval of aducanumab to treat Alzheimer's disease. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.05 Exodus from Academia and the Regretful FDA Approval of Aducanumab with Dr. Ameet Sarpatwari

Today we have a short monologue for you on just a few topics: a treatment algorithm for follicular lymphoma and our host Dr. Prasad's new paper out now in the European Journal of Clinical Investigation: "Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?" RCTs or Synthetic Control Arms?: doi.org/10.1111/eci.13580 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.04 Treatment Algorithm for Follicular Lymphoma & Assessing RCTs

Today we're back with another real-life (non-virtual!) interview. We're joined by Dr. Nina Shah of UCSF to discuss her career and her work in mutiple myeloma as well as the complexities of advancing your career -- dealing with productivity metrics like the h-index or the Kardashian index, switching institutions, balancing work with your home life, adapting to the changing field of oncology, and more. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.03 Multiple Myeloma, Productivity Metrics, and Field Changes in Oncology with Dr. Nina Shah

Today we sit down with Dr. George Sledge of the Stanford University Medical Center to hear the story of his career and to discuss the history of breast cancer research and treatment. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.02 The History of Breast Cancer Research and Treatment with Dr. George Sledge

Today we're launching season 4 of Plenary Session! This season we're returning to our love of monologues. On today's episode we talk about highlights from the recent annual meeting of the American Society of Clinical Oncology. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.01 Highlights from the 2021 ASCO Annual Meeting

On today's episode, we interview Dr. Marty Makary of Johns Hopkins School of Medicine and Bloomberg School of Public Health on how he chose his path in medicine, how health care as it is in the United States needs to change, and how groupthink dominated COVID-19 health policy. We discuss a variety of topics from his research on overuse, the prevalence of burnout in healthcare professionals, silos in medicine, to patients' lawsuits against hospitals. We touch on his two books, the latter of which has a new edition coming out next month that addresses COVID-19: Unaccountable: What Hospitals Won't Tell You and How Transparency Can Revolutionize Health Care, and "The Price We Pay: What Broke American Health Care--and How to Fix It". Unaccountable: https://www.bloomsbury.com/us/unaccountable-9781608198368/ The Price We Pay: https://www.bloomsbury.com/us/the-price-we-pay-9781635575910/ Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.90 Redesigning Health Care, Overuse, Burnout, and COVID-19 Groupthink with Dr. Marty Makary

Today we have a brief monologue for you on how to think about COVID-19 policy in the context of rare event and declining probabilities. We also touch on what to expect from season 4 of this podcast, as season 3 comes to an end. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.89 How to Think About COVID-19 Policy with Rare Events and Declining Probabilities

Today's episode is hosted by guest Logan Powell, an incoming medical student at the Texas A&M College of Medicine and creator of this podcast's show notes. He reverse interviews our usual host, Dr. Vinay Prasad, in honor of the one-year anniversary release of Dr. Prasad's book "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer". They explore a few behind-the-scenes stories. Show notes: www.plenarysessionpodcast.com Listen to Malignant with a free 30-day trial of Audible: www.audible.com/pd/B08864KFHW/?so…ACX0_195112_rh_us Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.88 Behind the Scenes for the One-Year Anniversary of Malignant with Dr. Vinay Prasad

A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from Oregon Health & Science University. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

hubhopper

Plenary Session

hubhopper